Indoco Remedies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDOCO, BSE:532612 Indoco Remedies Ltd.

Indoco Remedies Ltd.

03 Apr 2017

261.65

1.47%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

The USFDA has issued Indoco Remedies a warning letter for its Goa manufacturing facilities: unit 2 and 3. The warning letter was served to the company, following the USFDA inspection carried out during August 31September 4, 2016, for which Indoco had been issued six observations. These two units are located in the same complex and have been issued the same warning letter. Both facilities have been inspected five times by the USFDA since 2005. The USFDA has accepted five responses from the company but remains critical regarding the sixth response, which pertains to the leakage issue in a few products, especially for ophthalmic...

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

31 Jan 2017

261.65

1.47%

Result Updates

Sell: Indoco Remedies Ltd.

Angel Broking

Indoco Remedies posted lower than expected numbers for 3QFY2017. In sales, the company posted revenues of Rs272cr (Rs276cr expected) v/s Rs256cr in 3QFY2016, growth of 6.2% yoy. The lower growth was on the back of the formulation business at Rs252.2cr, up 4.5% yoy, API at Rs18.2cr up 32.8% yoy. The domestic formulation at Rs144.2cr record..

Indoco Remedies Ltd. has an average target of 325.00 from 2 brokers.

Indoco Remedies Ltd.

30 Jan 2017

261.65

1.47%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 6% YoY to | 278 crore (I-direct estimate: | 281 crore) mainly due to 6% YoY growth in domestic formulations to | 144 crore. Export formulation grew mere 3.6% YoY to | 108 crore, although, US formulations grew 27% YoY to | 38 crore EBITDA margins declined 358 bps YoY to 14.2% (I-direct estimate of 16.7%) mainly on account of higher YoY employee and R&D; costs. EBITDA declined 15%YoY to | 40 crore (I-direct estimate: | 47 crore)...

Indoco Remedies Ltd. has an average target of 325.00 from 2 brokers.

Indoco Remedies Ltd.

10 Nov 2016

261.65

1.47%

Indoco Remedies Ltd

Sell: Indoco Remedies Ltd.

Target

Angel Broking

Indoco Remedies posted sales of Rs276cr vs. Rs248cr in 2QFY16, up by 11.6% yoy, mainly on back of domestic sales (Rs168.8cr, which grew by 22.0% yoy). Overall, the formulations, which posted sales of RS261.4cr grew, by 13.0% yoy. The API (Rs135.9cr) dipped by 11.0% yoy. On the operating front, the gross margin came in at 64.9% (65.0% expe..

Indoco Remedies Ltd. has an average target of 325.00 from 2 brokers.

Indoco Remedies Ltd.

01 Nov 2016, 12:00AM

261.65

1.47%

Indoco Remedies

Buy: Indoco Remedies Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 10% YoY to | 281 crore (I-direct estimate: | 307 crore) mainly due to 22% growth in domestic formulations to | 169 crore. Export formulation grew 6% YoY to | 98 crore EBITDA margins fell 302 bps YoY to 14.9% (I-direct estimate: 17.7%) mainly due to an increase in employee cost and other expenditure. EBITDA fell 8% to | 42 crore (I-direct estimate: | 54 crore) Net profit declined 2% YoY to | 22 crore (I-direct estimate: | 30...

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

01 Aug 2016, 12:00AM

261.65

1.47%

Indoco Remedies

Buy: Indoco Remedies Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 15.2% YoY to | 257.4 crore (I-direct estimate: | 269.4 crore) mainly due to 18.4% YoY growth in export formulations to | 92.3 crore (I-direct estimates: | 115.6 crore). Domestic formulations grew 12.7% to | 142.1 crore (I-direct estimate: | 130.6 crore) EBITDA margins declined 238 bps YoY to 16.2% (I-direct estimate of 17.9%) mainly on account of an increase in employee expenditure...

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

17 Jun 2016

261.65

1.47%

Indoco Remedies Ltd

Sell: Indoco Remedies Ltd.

Angel Broking

Indoco Remedies (Indoco) results for 4QFY2016 have come in much below our expectations. The company posted a 20.5% yoy growth in sales to Rs255cr, although the same is lower than our expectation of Rs300cr. The growth was mainly driven by exports (Rs117.8cr), which grew by 43.8% yoy, while domestic sales (Rs136.3cr) rose 5.6% yoy. On the ..

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

30 May 2016

261.65

1.47%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 25.5% YoY to | 263 crore (I-direct estimate: | 269 crore) mainly due to 47.3% YoY growth in export formulations to...

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

02 Feb 2016, 12:00AM

261.65

1.47%

Indoco Remedies Ltd- Research Report

Hold: Indoco Remedies Ltd.

Angel Broking

For 3QFY2016, Indoco Remedies (Indoco) results were in line with our expectations on the sales front, while the net profit came in lower owing to a lower than expected OPM. The company posted sales of Rs255cr (V/s Rs257cr estimated), a growth of 19.6% yoy. The growth during the quarter came in through exports (Rs112.1cr) which rose 34.6% yoy, while domestic market sales grew 9.8% yoy to Rs141.9cr. On the operating front, the OPM came in at 15.4% V/s 18.3% in 3QFY2015 (and V/s an expected 16.5%). Thus, the net profit came in at Rs20.4cr V/s Rs21.6cr in 3QFY2015, a dip of 5.6% yoy. This is against our expectation of Rs25.4cr. Overall, we are Neutral on the stock. Results lower than expected: The company posted sales of Rs255cr (V/s Rs257cr estimated), a growth of 19.6% yoy. The growth during the quarter came in through exports (Rs112.1cr) which rose 34.6% yoy, while domestic market sales grew 9.8% yoy to Rs141.9cr. Exports growth during the period was aided by the regulated markets (Rs90.4cr) which grew 36.3% yoy and emerging markets (Rs139.0cr) which grew 32.6% yoy. On the operating front, the OPM came in at 15.4% V/s 18.3% in 3QFY2015 (and V/s an expected...